Tempest to Present at the Jefferies Healthcare Conference
June 06 2022 - 3:05PM
Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage
oncology company developing first-in-class1 therapeutics that
combine both targeted and immune-mediated mechanisms, today
announced that management will present at the Jefferies Healthcare
Conference on Wednesday, June 8, 2022 at 10:30 a.m. ET.
To access the live or archived recording of the
company presentation, please visit the investor section of the
Tempest website at https://ir.tempesttx.com.
About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage
oncology company advancing small molecules that combine both
tumor-targeted and immune-mediated mechanisms with the potential to
treat a wide range of tumors. The company’s two novel clinical
programs are TPST-1120 and TPST-1495, antagonists of PPARα and
EP2/EP4, respectively. Both TPST-1120 and TPST-1495 are advancing
through clinical trials designed to study both agents as
monotherapies and in combination with other approved agents. In
collaboration with F. Hoffmann La Roche, TPST-1120 is also
advancing in a randomized, global, Phase 1b/2 clinical study in
combination with the standard-of-care regimen of atezolizumab and
bevacizumab in the first-line treatment of patients with advanced
or metastatic hepatocellular carcinoma. Tempest is also developing
an orally-available inhibitor of TREX-1 designed to activate
selectively the cGAS/STING pathway, an innate immune response
pathway important for the development of anti-tumor immunity.
Tempest is headquartered in South San Francisco. More information
about Tempest can be found on the company’s website at
www.tempesttx.com.
Investor Contact:
Sylvia WheelerWheelhouse Life Science
Advisorsswheeler@wheelhouselsa.com
Media Contact:
Aljanae Reynolds Wheelhouse Life Science
Advisorsareynolds@tempesttx.com
____________________1 If approved
Tempest Therpeutics (NASDAQ:TPST)
Historical Stock Chart
From Jul 2024 to Jul 2024
Tempest Therpeutics (NASDAQ:TPST)
Historical Stock Chart
From Jul 2023 to Jul 2024